• LAST PRICE
    0.4113
  • TODAY'S CHANGE (%)
    Trending Down-0.0037 (-0.8916%)
  • Bid / Lots
    0.4110/ 8
  • Ask / Lots
    0.4500/ 1
  • Open / Previous Close
    0.4150 / 0.4150
  • Day Range
    Low 0.4072
    High 0.4367
  • 52 Week Range
    Low 0.3600
    High 1.8900
  • Volume
    33,216
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.415
TimeVolumeLPCN
09:32 ET3150.415
09:46 ET6680.4348
09:51 ET10000.4367
10:24 ET6000.4285
10:26 ET10000.4214
10:27 ET3000.42
10:29 ET3000.428499
10:36 ET1000.42
10:56 ET2000.428499
11:12 ET1000.42
11:21 ET86880.4102
11:36 ET2450.4259
11:52 ET1320.4113
12:28 ET24520.4285
12:37 ET1000.42
12:39 ET4530.420101
12:42 ET1000.42
12:44 ET27290.4261
12:50 ET1000.425
12:51 ET5000.4088
01:04 ET3000.4127
01:09 ET1000.41
01:58 ET5000.4163
02:02 ET1400.416399
02:14 ET1000.414
02:16 ET1000.414
02:38 ET2200.4164
02:57 ET1000.4108
03:14 ET1000.4108
03:17 ET10000.4108
03:19 ET1000.4108
03:21 ET1490.41
03:33 ET1000.4109
03:44 ET59300.4132
03:46 ET4000.413201
03:48 ET2000.4161
03:57 ET1000.41
04:00 ET4770.4113
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLPCN
Lipocine Inc
36.7M
8.8x
---
United StatesFNCH
Finch Therapeutics Group Inc
44.5M
-0.4x
---
United StatesAGLE
Aeglea Bio Therapeutics Inc
27.4M
-0.4x
---
United StatesSLDB
Solid Biosciences Inc
47.5M
-0.6x
---
United StatesICCC
ImmuCell Corp
54.8M
-70.6x
---
United StatesADAG
Adagene Inc
48.2M
-0.6x
---
As of 2022-12-07

Company Information

Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. It has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

Contact Information

Headquarters
675 S Arapeen Dr Ste 202SALT LAKE CITY, UT, United States 84108-1295
Phone
801-994-7383
Fax
801-994-7388

Executives

Independent Chairman of the Board, Lead Independent Director
Spyros Papapetropoulos
President, Chief Executive Officer, Director
Mahesh Patel
Principal Accounting Officer, Controller
Krista Fogarty
Vice President - Product Development
Nachiappan Chidambaram
Chief Medical Officer
George Nomikos

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$36.7M
Revenue (TTM)
$16.6M
Shares Outstanding
88.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.58
EPS
$0.05
Book Value
$0.52
P/E Ratio
8.8x
Price/Sales (TTM)
2.2
Price/Cash Flow (TTM)
9.0x
Operating Margin
20.95%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.